Klotho Neurosciences Reports Definitive Agreement & Equity Sales
Ticker: GRMLW · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1907223
Sentiment: neutral
Topics: material-agreement, equity-sale, financial-obligation
Related Tickers: KLTO
TL;DR
Klotho Neurosciences just signed a new deal and sold some stock. Watch KLTO.
AI Summary
Klotho Neurosciences, Inc. entered into a material definitive agreement on December 4, 2024, related to the creation of a direct financial obligation. The company also reported unregistered sales of equity securities. This filing follows a name change from ANEW Medical, Inc. on June 24, 2024.
Why It Matters
This filing indicates new financial obligations and equity transactions for Klotho Neurosciences, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details new financial obligations and unregistered equity sales, which can introduce financial risk and dilution concerns.
Key Players & Entities
- Klotho Neurosciences, Inc. (company) — Registrant
- December 4, 2024 (date) — Date of earliest event reported
- ANEW Medical, Inc. (company) — Former company name
- Redwoods Acquisition Corp. (company) — Former company name
- June 24, 2024 (date) — Date of name change
- 20241204 (date) — Conformed period of report
FAQ
What type of material definitive agreement did Klotho Neurosciences enter into?
The filing indicates the entry into a material definitive agreement that resulted in the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of the registrant.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 4, 2024.
What were Klotho Neurosciences' previous company names?
Klotho Neurosciences, Inc. was formerly known as ANEW Medical, Inc. and prior to that, Redwoods Acquisition Corp.
What is the SIC code for Klotho Neurosciences, Inc.?
The Standard Industrial Classification code for Klotho Neurosciences, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What other items are reported in this 8-K filing besides the material definitive agreement?
In addition to the material definitive agreement, the filing also reports on the creation of a direct financial obligation, unregistered sales of equity securities, and financial statements and exhibits.
Filing Stats: 867 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-12-10 16:41:18
Key Financial Figures
- $1,200,000 — (the "Note") in the principal amount of $1,200,000 pursuant to the terms of a securities p
- $0.25 — tock (the "Common Stock") at a price of $0.25 per share (the "Conversion Price"); pro
Filing Documents
- ea0224296-8k_klotho.htm (8-K) — 44KB
- ea022429601ex4-1_klotho.htm (EX-4.1) — 148KB
- ea022429601ex4-2_klotho.htm (EX-4.2) — 83KB
- 0001213900-24-107459.txt ( ) — 547KB
- klto-20241204.xsd (EX-101.SCH) — 3KB
- klto-20241204_def.xml (EX-101.DEF) — 26KB
- klto-20241204_lab.xml (EX-101.LAB) — 36KB
- klto-20241204_pre.xml (EX-101.PRE) — 25KB
- ea0224296-8k_klotho_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 10, 2024 KLOTHO NEUROSCIENCES, INC. By: /s/ Joseph Sinkule Name: Joseph Sinkule Title: Chief Executive Officer 2